ATORX — Alligator Bioscience AB Balance Sheet
0.000.00%
- SEK8.03m
- -SEK19.36m
- SEK0.51m
Annual balance sheet for Alligator Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 278 | 97.3 | 66.1 | 64.3 | 62.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 14.5 | 17.6 | 4.52 | 4.36 | 3.71 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 300 | 123 | 78.2 | 71.4 | 68.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15.4 | 26.9 | 20.3 | 3.02 | 1.87 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 333 | 170 | 118 | 104 | 111 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 47.4 | 64.5 | 99.1 | 201 | 78.1 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 50.9 | 80.5 | 107 | 235 | 104 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 282 | 89.1 | 11.9 | -131 | 6.86 |
| Total Liabilities & Shareholders' Equity | 333 | 170 | 118 | 104 | 111 |
| Total Common Shares Outstanding |